New-onset type 1 diabetes and Graves' disease after antiretroviral therapy in a patient with human immunodeficiency virus infection

被引:1
|
作者
Taguchi, Maho [1 ]
Ihana-Sugiyama, Noriko [1 ]
Shiojiri, Daisuke [2 ]
Izumi, Kazuo [1 ]
Kobayashi, Michi [1 ]
Kodani, Noriko [1 ]
Bouchi, Ryotaro [1 ]
Ohsugi, Mitsuru [1 ]
Tanabe, Akiyo [1 ]
Ueki, Kohjiro [1 ]
Kajio, Hiroshi [1 ]
机构
[1] Natl Ctr Global Hlth & Med, Ctr Hosp, Dept Diabet Endocrinol & Metab, Tokyo, Japan
[2] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Tokyo, Japan
关键词
Antiretroviral therapy; Immune-inflammatory reconstitution syndrome; Type; 1; diabetes; IMMUNE RECONSTITUTION;
D O I
10.1111/jdi.13965
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with human immunodeficiency virus (HIV) infection receiving antiretroviral therapy can develop autoimmune diseases, referred to as immune-inflammatory reconstitution syndrome. Nevertheless, only a few reports on the onset of type 1 diabetes as immune-inflammatory reconstitution syndrome are available. A 40-year-old Japanese man with HIV infection was initiated with antiretroviral therapy at the age of 29 years. He developed Graves' disease at 35 years and diabetes, with a hemoglobin A1c of 6.5%, and maintained insulin secretion at 38 years. His antiglutamic acid decarboxylase antibody level was >2,000 U/mL, and he was diagnosed with slowly progressive type 1 diabetes. At the age of 40 years, he was admitted to our hospital with diabetic ketosis. We retrospectively assayed his stored plasma samples for thyroid-stimulating hormone receptor antibody and antiglutamic acid decarboxylase antibody, which showed positive conversion after initiating antiretroviral therapy, suggesting that Graves' disease and type 1 diabetes developed as a probable result of immune-inflammatory reconstitution syndrome.
引用
收藏
页码:489 / 493
页数:5
相关论文
共 50 条
  • [31] Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection
    Meredith E. Childers
    Steven Paul Woods
    Scott Letendre
    J. Allen McCutchan
    Debralee Rosario
    Igor Grant
    Monica Rivera Mindt
    Ronald J. Ellis
    Journal of NeuroVirology, 2008, 14 : 550 - 557
  • [32] Questions about results reported with potent antiretroviral therapy for human immunodeficiency virus type 1 infection - Reply
    Zaunders, JJ
    Cunningham, PH
    Kaufmann, GR
    Cooper, DA
    JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04): : 1519 - 1520
  • [33] Antihypertensive therapy, new-onset diabetes, and cardiovascular disease
    Basile, J. N.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (04) : 656 - 666
  • [34] Case of newly onset type 1 diabetes after highly active antiretroviral therapy against HIV infection
    Kamei, Shinji
    Kaneto, Hideaki
    Hashiramoto, Mitsuru
    Hisano, Yuki
    Tanabe, Akihito
    Shimoda, Masashi
    Tawaramoto, Kazuhito
    Anno, Takatoshi
    Mune, Tomoatsu
    Matsuki, Michihiro
    Kaku, Kohei
    JOURNAL OF DIABETES INVESTIGATION, 2015, 6 (03) : 367 - 368
  • [35] Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
    Keymeulen, B
    Vandemeulebroucke, E
    Ziegler, AG
    Mathieu, C
    Kaufman, L
    Hale, G
    Gorus, F
    Goldman, M
    Walter, M
    Candon, S
    Schandene, L
    Crenier, L
    De Block, C
    Seigneurin, JM
    De Pauw, P
    Pierard, D
    Weets, I
    Rebello, P
    Bird, P
    Berrie, E
    Frewin, M
    Waldmann, H
    Bach, JF
    Pipeleers, D
    Chatenoud, L
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (25): : 2598 - 2608
  • [36] New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy
    Gursoy, Alptekin
    Cesur, Mustafa
    Erdogan, Murat Faik
    Corapcioglu, Demet
    Kamel, Nuri
    ENDOCRINE, 2006, 29 (03) : 513 - 516
  • [37] New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graves' ophthalmopathy
    Alptekin Gursoy
    Mustafa Cesur
    Murat Faik Erdogan
    Demet Çorapcioglu
    Nuri Kamel
    Endocrine, 2006, 29 : 513 - 516
  • [38] P glycoprotein in human immunodeficiency virus type 1 infection and therapy
    Sankatsing, SUC
    Beijnen, JH
    Schinkel, AH
    Lange, JMA
    Prins, JM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) : 1073 - 1081
  • [39] Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy
    Hance, AJ
    Lemiale, V
    Izopet, J
    Lecossier, D
    Joly, V
    Massip, P
    Mammano, F
    Descamps, D
    Brun-Vézinet, F
    Clavel, F
    JOURNAL OF VIROLOGY, 2001, 75 (14) : 6410 - 6417
  • [40] ANTIRETROVIRAL THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION - HOPE AND DESPAIR
    PICARD, O
    BIOMEDICINE & PHARMACOTHERAPY, 1994, 48 (02) : 85 - 88